Committee debates who controls medication decisions, reentry planning for MOUD in correctional facilities

Lawmakers and agency staff continued drafting language for H.32 on Feb. 21, pressing DOC contractors and health officials on how medications for opioid use disorder (MOUD) are provided in Vermont correctional facilities and how people leaving custody are connected to community care. The committee discussed who holds prescriptive authority in custody, which MOUD products should be allowed for initiation and transfer, screening timeframes, reentry planning and data collection.

The draft under consideration would keep a central clinical point of control inside the facility while preserving clinical consultation with outside providers. Tony Flom of the Department of Health’s substance‑use team said the operational practice is that "WellPath becomes the eyes and the ears" in the facility, but that hub providers may retain prescriptive authority under federal rules in hub‑and‑spoke arrangements. Dr. Yerleger (WellPath medical lead) confirmed that when someone already receives buprenorphine from a community prescriber, "the WellPath provider assumes all prescriptive authority" while consulting with the community prescriber; for methadone, federal regulations require the hub provider to maintain prescriptive control.

Why it matters: the committee aimed to align statutory language with current clinical and contractual practice while setting guardrails for continuity of care at release. Members pressed whether statute should require consultation with a community prescriber when one exists, whether the DOC contractor must offer counseling, and whether statutory language should authorize medication and short bridge supplies for detainees as well as sentenced offenders.

Screening and clinical thresholds. Committee members reviewed existing statutory screening timelines in current law: a physical assessment for inmates present at least 14 consecutive days, and a substance‑use screening within 24 hours of admission that includes opioid‑use…